Skip to content

Study · Randomized controlled trial · n = 92 · 2020

4 results

Exenatide and Renal Outcomes in Patients with Type 2 Diabetes and Diabetic Kidney Disease.

Wang X, Zhang H, Zhang Q, Guan M, Sheng S, Mo W, Zou M, Li J, Bi J, Tang X, Zeng H, He J, Xu G, Li P, Xue Y

American journal of nephrology23 Sept 2020Cited by 23 (Europe PMC)

PMID32966971 (opens in a new tab)PMCIDPMC7677996 (opens in a new tab)DOI10.1159/000510255 (opens in a new tab)PepBankPUB-32966971
Read at sourcePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In T2DM with DKD, exenatide plus glargine reduced UAER percentage change versus lispro plus glargine.

    In plain wordsIn T2DM with kidney disease, exenatide plus glargine reduced urine albumin more than lispro plus glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseUAER percentage change
    Study

    n = 92

    Comparator
    Insulin lispro plus glargine
    Analysis
    Primary
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    twice daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    After 24 weeks of treatment, the UAER percentage change was significantly lower in the intervention group than in the control group (p = 0.0255).
    2 context sentences
    Summary · context
    We performed a randomized parallel study encompassing 4 general hospitals.
    Summary · context
    T2DM patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 and macroalbuminuria, defined as 24-h urinary albumin excretion rate (UAER) >0.3 g/24 h were randomized 1:1 to receive exenatide twice daily plus insulin glargine (intervention group) or insulin lispro plus glargine…
  2. 02HumanRandomized controlled trialEfficacy outcome

    In T2DM with DKD, exenatide plus glargine reduced weight more than lispro plus glargine.

    In plain wordsIn T2DM with kidney disease, exenatide plus glargine reduced weight more than lispro plus glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseBody weight
    Study

    n = 92

    Comparator
    Insulin lispro plus glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    twice daily · 24 weeksAs given in this study (human).

    Measurements

    Weight decline
    1.3 kg
    intervention
    Between-group difference
    2.7 kg
    intervention versus control

    Source sentences

    Summary
    Moreover, the body weight declined by 1.3 kg in the intervention group (the difference between the 2 groups was 2.7 kg, p = 0.0001).
    2 context sentences
    Summary · context
    We performed a randomized parallel study encompassing 4 general hospitals.
    Summary · context
    T2DM patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 and macroalbuminuria, defined as 24-h urinary albumin excretion rate (UAER) >0.3 g/24 h were randomized 1:1 to receive exenatide twice daily plus insulin glargine (intervention group) or insulin lispro plus glargine…
  3. 03HumanRandomized controlled trialSafety outcome

    In T2DM with DKD, exenatide plus glargine produced less hypoglycemia than lispro plus glargine.

    In plain wordsIn T2DM with kidney disease, exenatide plus glargine produced less low blood sugar than lispro plus glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHypoglycemia frequency
    Study

    n = 92

    Comparator
    Insulin lispro plus glargine
    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    twice daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared to the control group, a lower frequency of hypoglycemia and more gastrointestinal AEs were observed in the intervention group.
    2 context sentences
    Summary · context
    We performed a randomized parallel study encompassing 4 general hospitals.
    Summary · context
    T2DM patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 and macroalbuminuria, defined as 24-h urinary albumin excretion rate (UAER) >0.3 g/24 h were randomized 1:1 to receive exenatide twice daily plus insulin glargine (intervention group) or insulin lispro plus glargine…
  4. 04HumanRandomized controlled trialSafety outcome

    In T2DM with DKD, exenatide plus glargine produced more gastrointestinal adverse events than lispro plus glargine.

    In plain wordsIn T2DM with kidney disease, exenatide plus glargine produced more digestive adverse events than lispro plus glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseGastrointestinal adverse events
    Study

    n = 92

    Comparator
    Insulin lispro plus glargine
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    twice daily · 24 weeksAs given in this study (human).

    Source sentences

    Summary
    Compared to the control group, a lower frequency of hypoglycemia and more gastrointestinal AEs were observed in the intervention group.
    2 context sentences
    Summary · context
    We performed a randomized parallel study encompassing 4 general hospitals.
    Summary · context
    T2DM patients with an estimated glomerular filtration rate (eGFR) ≥30 mL/min/1.73 m2 and macroalbuminuria, defined as 24-h urinary albumin excretion rate (UAER) >0.3 g/24 h were randomized 1:1 to receive exenatide twice daily plus insulin glargine (intervention group) or insulin lispro plus glargine…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.